Why the study?
Does Fasting 2-Deoxy-2-[18F]fluoro-d-glucose Positron Emission Tomography detect metabolic changes related to cardiac dysfunction in patients with Pulmonary Arterial Hypertension?
Does Fasting 2-Deoxy-2-[18F]fluoro-d-glucose Positron Emission Tomography detect metabolic changes related to cardiac dysfunction in patients with Pulmonary Arterial Hypertension?
Metabolic imaging with FDG-PET may be useful for therapeutic monitoring of patients with pulmonary arterial hypertension by tracking pathologic glycolytic metabolism.
May enable FDG-PET monitoring of PAH cardiac metabolism; leaves open effects on outcomes or therapy.
PAH hearts have pathologic glycolytic metabolism that is quantitatively related to cardiac dysfunction over time, suggesting that metabolic imaging may be useful in therapeutic monitoring of patients.
No takes yet. Share an insight, caveat, or question.
Lundgrin et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: